EveryONE Medicines
Nessan Bermingham is an accomplished professional with extensive background in biotechnology and venture capital. Currently serving as an Operating Partner at Khosla Ventures since December 2021, Bermingham also holds board member positions at multiple organizations, including Ochre Bio, CellFE, Deep Genomics, and Liberate Bio, the latter of which Bermingham founded. As Interim CEO and a board member at EveryONE Medicines, Inc., Bermingham has made significant contributions to the field. Previous roles include Founder and Executive Chair at Korro Bio, Inc., Chairperson at F-star Therapeutics, and CEO of Triplet Therapeutics. Bermingham's academic credentials include a Doctor of Philosophy in Molecular Biology from Imperial College London and postdoctoral research at Baylor College of Medicine.
This person is not in any teams
EveryONE Medicines
EveryONE Medicines is committed to developing individualized precision medicines targeting genetic variants causing fatal, neurodegenerative diseases unique to just a few or even ONE patient. Momentum is building as technological advances with genomic testing and the prevalence of testing is improving rapidly to identify the rarest of rare mutations. Through a collaborative effort across all stakeholders in the treatment and diagnosis of rare genetic disease, EveryONE Medicines will bring a scalable solution to meet the needs of the individual patient who currently has limited hope.